Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Solid Tumor 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × tislelizumab × Clear all
NCT05661955 2026-05-11

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

BeOne Medicines

Phase 1/2 Active not recruiting
113 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

Phase 1/2 Completed
44 enrolled
GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡